Login to Your Account

RuiYi, Genor Blaze Trail in China with JV for Rheumatoid Arthritis

By Dave Silver
Staff Writer

Thursday, May 16, 2013

TAIPEI, Taiwan – In what is likely one of the first attempts by a foreign biopharma to complete the full range of clinical trials in China for a new biologic, leading to regulatory and market approval by Chinese drug approval authorities, therapeutic antibodies specialist RuiYi Inc., of La Jolla, Calif., and Shanghai, entered a collaboration agreement with Genor BioPharma Co. Ltd., of Shanghai, to develop its anti-IL-6 monoclonal antibody RYI-008 for rheumatoid arthritis (RA).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription